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Myeloproliferative neoplasms (MPNs) can be classified according to 
the 2008 World Health Organization classification[1] into Philadelphia 
(Ph) chromosome-negative and positive neoplasms. Ph chromosome-
negative neoplasms include polycythaemia vera (PV), essential 
thrombocythaemia (ET) and primary myelofibrosis (PMF), whereas 
chronic myeloid leukaemia (CML) comprises Ph chromosome-
positive neoplasms.
The Janus Kinase 2 (JAK2) mutations found in 50 - 60% of patients 
encode a cytoplasmic tyrosine kinase protein active in the JAK/signal 
transducer and activator of transcription proteins (STAT) signalling 
pathway. A gain-of-function mutation replaces a guanidine base with 
a thymine base, resulting in a valine-to-phenylalanine alteration,[2] 
and consequently constitutive tyrosine kinase activity along with 
enhanced proliferation of myeloid cells. In 5 - 10% of patients the 
thrombopoietin receptor (MPL) gene is impaired, while in 30 - 45% 
of patients no specific molecular marker had been described until the 
discovery of calreticulin (CALR). In these 30 - 45% of patients CALR 
was shown to be the second most frequent mutation after JAK2, 
offering mutual exclusivity to JAK2 and MPL mutations, and being 
absent in PV patients.[2]
The CALR gene, mapped to chromosome 19p,[3] has three 
structural and functional domains, referred to as the N, P and C 
domains.[4] The N domain is important for proper folding of CALR 
and enables its interaction with numerous other protein molecules 
such as α-integrin. The P domain comprises specific amino acid 
sequence repeats permitting binding of high-affinity calcium ions 
(Ca2+) and lectin-like chaperoning.[5] The C domain contains a KDEL 
signal comprising four acidic amino acids (K = Lys, D = Asp, E = Glu, 
L = Leu) that allow CALR to have a high capacity for binding Ca2+, 
thus regulating CALR’s interaction with other protein molecules.[6]
Of the 36 types of insertions and deletions identified, type  1 (a 
52-base pair deletion) and type 2 (a 5-base pair insertion) mutations 
account for >80% of CALR mutations.[7] Phenotypic differences 
between type 1 and type 2 carriers have been implicated. [3] All 
recurrent mutations cause a frameshift in the region encoding 
the C domain, leading to altered subcellular localisation[2] and 
impaired function. Two main functions have been indicated, a 
chaperone function essential in protein processing and transport in 
the endoplasmic reticulum (ER), ultimately eliminating incorrectly 
folded proteins, and a regulatory function over intracellular Ca2+ 
levels whereby CALR acts as a sensor and buffer to Ca2+ in the ER 
lumen. Despite inconclusive evidence regarding the mechanism by 
which CALR assists protein folding and Ca2+ homoeostasis,[5] its 
depletion has profound effects.
Methods
Samples
Eighty-nine archived samples from patient and control groups, 
including all samples of patients suspected of having an MPN, were 
screened. There were JAK2-positive and negative and ET, PV and 
PMF samples. The patient group consisted of JAK2-negative samples, 
whereas the control group consisted of JAK2-positive samples, as 
CALR and JAK2 are thought to be mutually exclusive. DNA was 
extracted and purified using the Promega Purification Kit (Promega, 
USA) (www.promega.com/protocols/).
Polymerase chain reaction (PCR) and amplicon analysis
Published primers[2] targeting exon 9 of CALR were used (Applied 
Biosystems, UK). A primer-based sizing assay was used to detect 
CALR mutations, the forward primer (GGCAAGGCCCTGAGGTGT) 
being labelled with 6-carboxyflourescein (6-FAM). The reverse 
primer sequence was GGCCTCAGTCCAGCCCTG.
Hot-start PCR was used. The amplicons labelled with 6-FAM were 
electrophoresed in a 3130 Genetic Analyser (Applied Biosystems, 
UK), as well as on agarose gel.
A mixture of 10 µL Hi-Di Formamide and 0.5 µL GeneScan 
LIZ  500 (size standard), both from Life Technologies, USA, was 
prepared for capillary electrophoresis, of which 10 µL was added 
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to 1.5 µL PCR product. Nested PCR was 
performed for the samples subjected to gel 
electrophoresis, whereby the PCR products 
were amplified for a second time in an ABI 
2700 thermocycler (Applied Biosystems, 
USA). PCR products were separated on 
a 2.5% agarose gel and analysed under 
ultraviolet light. Samples positive for a 
mutation were band-stabbed and placed in 
TE-1 buffer (EDTA 0.5M, Tris 1M) overnight 
at 4°C. Four µL of the supernatant was used 
for sequencing.
The wild-type allele has 267 base pairs. [8] 
Any fragments that differed in size to the 
wild-type allele carried a mutation.
DNA sequence analysis
Sequencing of samples was performed using 
the BigDye Terminator v3.1 Ready Reaction 
Cycle Sequencing Kit (Applied Biosystems, 
USA). The sequencing products were 
purified using the ethanol/sodium acetate 
precipitation method. A volume of 25 µL 
Hi-Di Formamide was added to the pellet 
and the samples were run on an ABI Prism 
3130 Genetic Analyser (Applied Biosystems, 
UK).
The sequencing reactions were analysed 
using Sequencing Analysis Software (version 
5.3.1) (Applied Biosystems, UK). Two free 
online programs were used, Chromas 
version 2.4.3 (Technelysium, Australia) 
(www.technelysium.com.au/chromas_lite.
html), which visualised the sequencing data, 
and Lalign (www.ch.embnet.org/software/
LALIGN_form.html), which compared the 
sequencing data with a reference sequence 
obtained from Ensembl[8] using the 
algorithm of Huang and Miller.[9]
Ethical considerations
The University of the Free State Faculty of 
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Results
The melting temperatures for all reactions 
were optimised at 69°C. Of the 89 samples, 
only three showed a 52-base pair deletion. 
With two samples, two distinct peaks were 
observed, one at 263 base pairs and the other 
at 210 base pairs. With the other sample, 
one distinct peak was observed at 210 base 
pairs, making it homozygous for the type 1 
deletion. Fig. 1 depicts electropherograms 
of (A) a patient with no CALR mutation 
present, and (B) a patient with a mutated 
CALR.
DNA fragments separated on a 2.5% 
agarose gel confirmed three samples positive 
for a 52-base pair deletion. Again, of the three 
samples, two were heterozygous and one was 
homozygous for a 52-base pair deletion in 
CALR. Fig. 2 shows a gel electropherogram 
of all samples positive for a CALR type 1 
mutation. Included is a molecular weight 
marker sizing the fragments between 200 
and 300 base pairs. The online program 
Lalign allowed for comparison of a reference 
sequence of CALR with the sequencing 
product. All three samples showed a 52-base 
pair deletion.
Discussion
CALR mutations were identified in three 
patients, all of which accounted for a type 1 
mutation. Two were heterozygous for a 
52-base pair deletion, while the other was 
homozygous. The JAK2 and CALR muta-
tions were thought to be mutually exclusive, 
but the homozygous sample was double-
positive for both JAK2 and CALR. Studies 
have described similar cases in patients 
with ET, but not in those with PV, and the 
implications relating to clinical presenta-
tion and prognosis of these patients are 
unclear. The heterozygous samples were 
from patients with a typical ET phenotype, 
and the homozygous sample had a PV 
phenotype.
The loss of CALR function can be 
observed by the onset of disease due to a 
frameshift to an alternative reading frame 
occurring in the C-terminus, obscuring 
CALR’s pleotropic role. The C-terminus is 
coded by exon 9 of CALR, which includes 
an ER retention signal. With the generation 
of a new C-terminus, through replacement 
with a positively charged polypeptide chain 
rich in arginine and methionine, the ER 
KDEL retention signal is lost. CALR’s roles 
are related to its distribution in the ER, in 
cytosol and on the cell surface. It resides 
mainly in the ER, where it performs its 
pleotropic functions ranging from Ca2+ 
regulation to ensuring proper protein 
folding. If the ER KDEL retention signal is 
lost, CALR therefore cannot be localised, 
or perform its critical functions in many 
biological processes including proliferation, 
apoptosis and immunogenic cell death.[10] 
When CALR is overexpressed, it suppresses 
cell proliferation and enhances apoptosis, 
which is triggered by Ca2+ release from 
the ER. Disabled cellular responses are 
therefore seen when there is a loss of CALR. 
In addition, it promotes the phagocytic 
function of macrophages to engulf hazardous 
cancerous cells. When CALR is mutated, 
there is therefore decreased phagocytosis of 
cancer cells.[3]
The unanticipated functional involve-
ment of the JAK/STAT proteins signalling 
pathway alongside CALR demon strates a 
transcriptional JAK2 signalling signature 
consistent in all MPN patients regardless of 
clinical phenotypes or mutational status. [3] 
This signature, present in patients with a 
mutated CALR, could elucidate the double-
positive cases. Cells expressing type 1 CALR 
mutations proliferate independently of 
interleukin 3 (IL-3). This hypersensitivity 
to IL-3 hypothesis was confirmed by the 
phosphorylation of STAT5 in the presence and 
absence of IL-3. Increased phosphorylation 
of STAT5 was observed in the absence of 
IL-3, supporting the hypothesis that the 
JAK/STAT signalling pathway is activated in 
type 1 CALR mutations.[10]
Some data also suggest preferential expan-
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Fig. 2. Agarose gel picture samples positive for 
the CALR deletion 52 mutation. Sample 1 is 
homozygous and samples 2 and 3 are hetero­
zygous. The x-axis indicates the molecular 
weight marker (MWM) and patient samples. The 
y-axis indicates the fragment size of the MWM 
measured in base pairs.
Fig. 1. Capillary electropherograms depicting 
sam ples with (A) wild­type CALR, and (B) 52­
base pair CALR deletion.
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result of CALR’s inability to export Ca2+ from the ER, keeping the 
calcineurin-nuclear factor of activated T cells (NFAT) signalling 
pathway notably less active. This in turn favours the megakaryocyte 
cell lineage instead of the erythroid lineage, providing an explanation 
as to why two heterozygous samples were observed in patients 
with high platelet counts. CALR expression in erythroblasts and 
granulocytes is also downregulated from CD34+ cells, suggesting 
CALR’s crucial role in platelet functions.[5] In contrast to mutant 
CALR only being observed in ET and PMF, the homozygous sample 
was found in a patient suspected of having PV.
Conclusions
The clinical outcomes of CALR differ from those of JAK2 and MPL. 
CALR mutations are associated with prognostic advantages such as 
a lower thrombotic risk, longer median survival, and a more benign 
course of disease.[3] Since CALR mutations are associated with better 
outcomes, these clinical outcomes are useful in future prognostic 
and therapeutic indications of Ph chromosome-negative disorders. 
Knowledge of CALR mutations can therefore allow for a more 
definitive classification of myeloproliferative neoplasms.
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